title: Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods.
abstract: Zidovudine (Zdv) is widely used to reduce maternal-infant human immunodeficiency virus transmission (HIV), but its consequences for disease progression among children infected despite Zdv exposure remain unknown. In a multicenter observational cohort study of 325 HIV-infected children born during 1986-1997, clinical progression was compared among infected children exposed or unexposed to Zdv during prenatal and perinatal periods. Zdv exposure was associated with 1.8-fold (95% confidence interval, 1.02-3.11) increased risk of progressing to AIDS or death after adjusting for year of birth, maternal CD4 cell count, maternal AIDS diagnosis, and subsequent antiretroviral therapy of the child. Mean log(10) viral copies at 7-12 weeks were higher among Zdv-exposed children (P=.004). No infected child treated early with multidrug therapy progressed to AIDS or died by 1 year, regardless of early Zdv exposure. More rapid disease progression was observed among infected children exposed during pregnancy or birth to Zdv if effective multidrug therapy was not initiated.
authors.affiliation: Columbia University, Sergievsky Center, New York, NY 10032, USA. lk24@columbia.edu
authors.forename: L
authors.initials: L
authors.lastname: Kuhn
authors.forename: E J
authors.initials: EJ
authors.lastname: Abrams
authors.forename: J
authors.initials: J
authors.lastname: Weedon
authors.forename: G
authors.initials: G
authors.lastname: Lambert
authors.forename: E E
authors.initials: EE
authors.lastname: Schoenbaum
authors.forename: S R
authors.initials: SR
authors.lastname: Nesheim
authors.forename: P
authors.initials: P
authors.lastname: Palumbo
authors.forename: P E
authors.initials: PE
authors.lastname: Vink
authors.forename: M
authors.initials: M
authors.lastname: Bulterys
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D018450:Disease Progression; D006678:HIV / Q000187:drug effects / Q000502:physiology*; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology* / Q000635:transmission / Q000821:virology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care; D018743:Perinatal Care; D011295:Prenatal Care; D012367:RNA, Viral / Q000378:metabolism; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D015215:Zidovudine